

64  
600 expression of the heterologous protein is regulated in a tissue specific manner.

---

### REMARKS

This submission is in response to the Official Action dated January 14, 2003. Claims 28, 33, 38 and 39 have been amended. Claims 29 and 34 have been allowed. Claims 28-39 are currently pending.

Claims 28 and 33 have been amended to recite that the level of activity of the Sp1 or B segment-binding  $\beta_3$ -AR *trans*-activating factor results in an increase (claim 28) or a decrease (claim 33) in the level of  $\beta_3$ -AR gene product. Support for this amendment can be found throughout the specification and in particular on page 27 lines 4-9 and page 29 line 5 - page 30 line 3.

Claims 38 and 39 have been amended to provide antecedent basis for the phrases in sections (iii) and (iv) of the claims objected to by the Examiner.

No new matter has been added by these amendments.

Reconsideration of the above identified application, in view of the above amendments and the following remarks, is respectfully requested.

### **REJECTIONS UNDER 35 USC § 112, FIRST PARAGRAPH**

Claim 28 (and its dependent claims 31 and 32) and claim 33 (and its dependent claims 36 and 37) have been rejected for alleged failure to fulfill the

written description requirement. Specifically, the Examiner alleges that the phrase "in a level of activity" encompasses literally any activity that may be associated with Sp1 or B segment-binding  $\beta_3$ -adrenergic receptor trans-activating factors and that the specification only describes these activities in relation to expression of the  $\beta_3$ -adrenergic receptor gene. The Examiner has indicated that this rejection would be overcome if the detection of activity was linked to  $\beta_3$ -adrenergic receptor gene expression.

As recommended by the Examiner, claims 28 and 33 have been amended to recite that the level of activity results in an increase (or decrease) in the level of  $\beta_3$ -AR gene product. These amendments do not narrow the scope of the claims. It is believed that the rejections of claims 28 and 33 have been obviated and Applicants respectfully request that these rejections be withdrawn.

#### **REJECTIONS UNDER 35 USC § 112, SECOND PARAGRAPH**

Claims 30 and 35 have been rejected as indefinite because the end result of the claim allegedly does not necessarily match the preamble of the claim. Specifically, the Examiner contends that the amount of the transcription factor does not necessarily correlate to the level of activity of the transcription factor.

Applicants respectfully disagree. The art generally recognizes a correlation between the amount of transcription factor and its activity. The

correlation between amount of transcription factor and its activity is the principle behind assays standard in the field such as gel shift assays. In addition, assays to detect the amount of Sp1 or B segment-binding  $\beta_3$ -AR *trans*-activating factor associated with nucleic acid containing the B segment core binding sequence are described in the specification as assays appropriate for screening for compounds that increase or decrease the activity of  $\beta_3$ -AR trans-activating factors (see e.g. page 30 lines 9-17). Accordingly, Applicants respectfully request withdrawal of this rejection.

The Examiner has rejected claim 31 as indefinite. Specifically, the Examiner contends that the term "express at a very low level,  $\beta_3$ -AR" is not defined clearly in the specification.

Applicants respectfully disagree. Page 29 lines 11-18 of the specification gives several examples of cells that express  $\beta_3$ -AR at very low levels (WAT cells, muscle cells, liver cells, HeLa and CV-1 cells) and explains that the level of expression of  $\beta_3$ -AR in these cells is very low *relative* to  $\beta_3$ -AR-expressing cells. The phrase "relative to  $\beta_3$ -AR-expressing cells" defines what "very low levels" means by relating the level to specific levels known in the art (e.g. the level expressed in WAT, muscle, liver, HeLa and CV-1 cells).

The specification also discloses other examples of cells that express  $\beta_3$ -AR at low levels. For example, page 5 lines 11-13 of the specification states

that  $\beta_3$ -AR is expressed by mouse brown adipose tissue cells, but is expressed at very low levels by human white adipocytes. See also page 51 lines 25-28 of the specification. The specification also points to two references (Wilson *et al.*, The Journal of Pharmacology and Experimental Therapeutics 279:214-221, 1996, cited on page 3 lines 19-20 of the specification and Strosberg, Annu. Rev. Pharmacol. Toxicol., 37:421-450, 1997, cited on page 51 lines 23-24 of the specification) that demonstrate low levels of  $\beta_3$ -AR expression. Thus, one skilled in the art could readily determine low levels of  $\beta_3$ -AR expression and could also readily identify cells that "express at a very low level,  $\beta_3$ -AR." Accordingly, Applicants believe this rejection has been overcome and respectfully request that this rejection be withdrawn.


The Examiner has also rejected claims 38 and 39 for alleged indefiniteness because of an alleged lack of antecedent basis for the phrases "the sequence that is greater than 80% identical to the nucleotide sequence" and "the Sp1-binding site." Claims 38 and 39 have been amended to provide antecedent basis for these phrases. Thus, this rejection has been obviated and Applicants respectfully request withdrawal of this rejection.

## CONCLUSION

Therefore, in view of the above amendments and remarks, it is respectfully requested that the application be reconsidered and that all pending claims be allowed and the case passed to issue.

If there are any other issues remaining which the Examiner believes could be resolved through either a Supplemental Response or an Examiner's Amendment, the Examiner is respectfully requested to contact the undersigned at the telephone number indicated below.

Respectfully submitted,

A handwritten signature in black ink, appearing to read "Paul F. Fehlner", written over a horizontal line.

Paul F. Fehlner, Ph.D.  
Reg. No. 35,135  
Attorney for Applicants

DARBY & DARBY, P.C.  
Post Office Box 5257  
New York, NY 10150-5257  
Phone (212) 527-7700

M:\0630\1e791us1\HME0626.WPD

EXPRESS MAIL CERTIFICATE

4/14/03 294039683-US  
Date Label No.

I hereby certify that, on the date indicated above, this paper or fee was deposited with the U.S. Postal Service & that it was addressed for delivery to the Assistant Commissioner for Patents, Washington, DC 20231 by "Express Mail Post Office to Addressee" service.

PLEASE CHARGE ANY DEFICIENCY UP TO \$300.00 OR CREDIT ANY EXCESS IN THE FEES DUE WITH THIS DOCUMENT TO OUR DEPOSIT ACCOUNT NO. 04-0100

D. B. Beck  
Name (Print) Signature

Customer No.



Docket No: 0630/1E791-US1

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: Vedrana S. SUSULIC; Emir DUZIC

Serial No.: 09/761,116

Art Unit: 1636

Confirmation No.: 3094

Filed: January 16, 2001

Examiner: Leffers Jr., Gerald

For: TRANSCRIPTIONAL REGULATION OF THE HUMAN BETA3 - ADRENERGIC RECEPTOR GENE

MARK-UP AMENDMENT

Hon. Commissioner of  
Patents and Trademarks  
Washington, DC 20231

April 14, 2003

Sir:

28. (Twice Amended) A method of screening for a compound that

increases activity of an Sp1 or B segment-binding  $\beta_3$ -adrenergic receptor ( $\beta_3$ -AR) *trans*-activating factor in human cells, which method comprises:

- (a) contacting cells capable of producing the Sp1 or B segment-binding  $\beta_3$ -AR *trans*-activating factor with a test compound; and
- (b) detecting an increase in a level of activity of the Sp1 or B segment-binding  $\beta_3$ -AR *trans*-activating factor,

wherein the increase in the level of activity of the Sp1 or B segment-binding  $\beta_3$ -AR *trans*-activating factor results in an increase in the level of  $\beta_3$ -AR gene product relative to a level of expression prior to contact with the test compound.

33. (Twice Amended) A method of screening for a compound that inhibits activity of an Sp1 or B segment-binding  $\beta_3$ -adrenergic receptor ( $\beta_3$ -AR) *trans*-activating factor in human cells, which method comprises:

- (a) contacting cells capable of producing the Sp1 or B segment-binding  $\beta_3$ -AR *trans*-activating factor with a test compound; and
- (b) detecting a decrease in a level of activity of the Sp1 or B segment-binding  $\beta_3$ -AR *trans*-activating factor,

wherein the decrease in the level of activity of the Sp1 or B segment-binding  $\beta_3$ -AR *trans*-activating factor results in a decrease in the level of  $\beta_3$ -AR gene product relative to a level of expression prior to contact with the test compound.

38. (Amended) A method of screening for a compound that increases activity of a  $\beta_3$ -adrenergic receptor ( $\beta_3$ -AR) *trans*-activating factor in human cells, which method comprises:

- (a) contacting cells capable of producing the  $\beta_3$ -AR *trans*-activating factor with a test compound; and
- (b) detecting an increase in a level of activity of the  $\beta_3$ -AR *trans*-activating factor,

wherein the level of activity of the  $\beta_3$ -AR *trans*-activating factor is detected by an increase in the level of expression of a reporter gene operatively associated with an isolated nucleic acid selected from the group consisting of:

- (i) about a 7 kb genomic DNA 5' flanking region of a  $\beta_3$ -AR transcription start site,
- (ii) a deletion construct of a 7 kb genomic DNA located upstream of a  $\beta_3$ -AR transcription start site;
- (iii) a nucleic acid [wherein the] comprising a nucleotide sequence that is greater than 80% identical to the nucleotide sequence GCCTCTGGGGAG (SEQ ID NO:1) [is] located 5' to [the] an Sp-1 binding site relative to a transcription start site; and
- (iv) a nucleic acid comprising a heterologous coding sequence



operatively associated with a promoter and operatively associated with [the] a nucleotide sequence that is greater than 80% identical to the nucleotide sequence GCCTCTGGGGAG (SEQ ID NO:1) in proximity to [the] an Sp-1 binding site, whereby expression of the heterologous protein is regulated in a tissue specific manner.

39. (Amended) A method of screening for a compound that decreases activity of a  $\beta_3$ -adrenergic receptor ( $\beta_3$ -AR) *trans*-activating factor in human cells, which method comprises:

- (a) contacting cells capable of producing the  $\beta_3$ -AR *trans*-activating factor with a test compound; and
- (b) detecting [an] a decrease in a level of activity of the  $\beta_3$ -AR *trans*-activating factor, wherein the level of activity of the  $\beta_3$ -AR *trans*-activating factor is detected by [an] a decrease in the level of expression of a reporter gene operatively associated with an isolated nucleic acid selected from the group consisting of:
  - (i) about a 7 kb genomic DNA 5' flanking region of a  $\beta_3$ -AR transcription start site,
  - (ii) a deletion construct of a 7 kb genomic DNA located upstream of a  $\beta_3$ -AR transcription start site;

(iii) a nucleic acid [wherein the] comprising a nucleotide sequence that is greater than 80% identical to the nucleotide sequence GCCTCTGGGGAG (SEQ ID NO:1) [is] located 5' to [the] an Sp-1 binding site relative to a transcription start site; and

(iv) a nucleic acid comprising a heterologous coding sequence operatively associated with a promoter and operatively associated with [the] a nucleotide sequence that is greater than 80% identical to the nucleotide sequence GCCTCTGGGGAG (SEQ ID NO:1) in proximity to [the] an Sp-1 binding site, whereby expression of the heterologous protein is regulated in a tissue specific manner.